Finch and Takeda Collaborate on IBD Therapies

News
Article

The companies will work to co-develop FIN-524, a live biotherapeutic product composed of cultured bacteria strains.

On April 5, 2017, Finch Therapeutics and Takeda Pharmaceutical Company announced that they have entered into a global collaboration agreement to jointly develop FIN-524, a live biotherapeutic product in pre-clinical research. FIN-524 is composed of cultured bacterial strains that have been linked to favorable clinical outcomes in studies of microbiota transplantations in Inflammatory Bowel Disease (IBD).

Under the terms of the agreement, Takeda will make an upfront payment of $10 million to Finch for the exclusive worldwide rights to develop and commercialize FIN-524 and rights to follow-on products in IBD. Finch will be eligible for development, regulatory, and commercial financial milestones and tiered royalties on worldwide net sales. Finch and Takeda may elect to extend this collaboration to additional, related indications on similar terms. Further details of the agreement were not disclosed.

Source: Finch Therapeutics

Recent Videos
Tore Bergsteiner from MAIN5 details his predictions for how the mega trends will shape the bio/pharma industry in 2025 and beyond.
Roger Viney from ICE Pharma discusses the quality and compliance issues surrounding the use of animal-derived ingredients in the bio/pharma industry.
Tore Bergsteiner from MAIN5 discusses the most pertinent and impactful bio/pharma industry trends from 2024.
Related Content